Abbott

175 articles about Abbott

• Abbott's TriClip™ Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair

  4/9/2020

  Abbott (NYSE: ABT) today announced that its TriClip™ Transcatheter Tricuspid Valve Repair System has received CE Mark and is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical treatment for people with a leaky tricuspid valve, a condition known as tricuspid regurgitation (TR).

• Abbott's FreeStyle® Libre 14 Day System Now Available in U.S. for Hospitalized Patients with Diabetes During COVID-19 Pandemic

  4/8/2020

  Abbott (NYSE: ABT) announced today that the FreeStyle Libre 14 day system, the world's leading3 continuous glucose monitoring (CGM) technology, can now be used in the hospital setting2 during the COVID-19 pandemic, according to the U.S. Food and Drug Administration (FDA)

• Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes

  3/27/2020

  Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes

• Abbott Declares 385th Consecutive Quarterly Dividend

  2/21/2020

  The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 36 cents per share.

• New Real-World Data Show that Abbott's FreeStyle Libre System Delivers Positive Health Outcomes for People with Type 1 and Type 2 Diabetes

  2/20/2020

  Abbott (NYSE: ABT) announced today that four real-world data abstractsi,ii,iii,iv are being presented during the 13th Advanced Technologies & Treatments for Diabetes (ATTD) in Madrid.

• Abbott Introduces Next-Generation Heart Rhythm Management Devices in Europe, Featuring State-of-the-Art Patient App and Bluetooth Connectivity

  2/18/2020

  Abbott (NYSE: ABT) today announced it has received CE Mark for the new Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, bringing the most advanced heart rhythm management capabilities along with a new set of benefits to people in Europe with abnormal heart rhythms and heart failure.

• Abbott's In-Development Fully Implantable Heart Pump System Earns FDA's Breakthrough Device Designation

  2/4/2020

  Abbott (NYSE: ABT) today announced that the company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its in-development Fully Implantable Left Ventricular Assist System (FILVAS).

• Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke

  2/3/2020

  - The CATALYST trial will examine Abbott's Amplatzer™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation

• Abbott's Tendyne™ Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation

  1/30/2020

  Abbott (NYSE: ABT) today announced that its Tendyne™ Transcatheter Mitral Valve Implantation (TMVI) system received CE Mark and is now approved for use in Europe.

• Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson's Disease

  1/24/2020

  Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication for the company's Infinity™ Deep Brain Stimulation (DBS) system to include targeting of an area of the brain called the internal globus pallidus (GPi).

• Abbott Reports Fourth-Quarter 2019 Results; Announces Strong Forecast for 2020

  1/22/2020

  Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2019.

• Abbott to Initiate Trial to Study MitraClip as an Option for Moderate Surgical Risk Patients

  1/13/2020

  New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population

• FDA Approves Less Invasive Surgical Approach for Abbott's Heart Pump to Help Patients Avoid Open Heart Surgery

  1/7/2020

  For people battling advanced heart failure, Abbott's HeartMate 3 heart pump can now be implanted through an incision in the chest wall versus open heart surgery

• Abbott Raises Quarterly Dividend 12.5%, Increasing Payouts for 48 Straight Years

  12/13/2019

  The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 36 cents per share – a 12.5% increase.

• Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020

  11/13/2019

  Abbott (NYSE: ABT) today announced that Miles D. White will be stepping down as Chief Executive Officer on March 31, 2020, after a remarkable 21-year tenure, the second longest for a non-founder in today's S&P 100. He will remain Executive Chairman of the Board.

• Abbott Announces Discovery of New Strain of HIV, Keeping Global Health Community a Step Ahead of the Virus

  11/6/2019

  Discovery marks the first time a new subtype of HIV-1 has been identified since 2000

• The Australian Red Cross Blood Service Selects Abbott's Alinity s Solution for Blood and Plasma Screening

  10/21/2019

  Abbott (NYSE: ABT) today announced the Australian Red Cross Blood Service (Australian Blood Service) has signed a multiple-year agreement for Abbott's most advanced blood and plasma screening technology, Alinity™ s System.

• Abbott Reports Third-Quarter 2019 Results

  10/16/2019

  Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2019.

• Abbott and Omada Health Partner to Offer Integrated Digital Health and Coaching Experience for People with Type 2 Diabetes

  10/14/2019

  Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes

• Late-Breaking Data Shows Abbott's MitraClip™ is Cost Effective, Increases Life Expectancy and Improves Quality of Life

  9/29/2019

  New late-breaking data at TCT 2019 demonstrate that Abbott's MitraClip™ is cost-effective for heart failure patients with significant secondary mitral regurgitation compared to guideline-directed medical therapy alone